SAN DIEGO, August 22, 2025 — Leads & Copy — Gyre Therapeutics (Nasdaq: GYRE) has appointed Dan Weng, M.D., to its Board of Directors, effective August 18, 2025. Dr. Weng has served as President and CEO of Medelis, Inc., since 2018. He previously held executive positions at EPS International Holding Co., MedPace, Inc., ICON Plc, PharmaNet Development Group, and Quintiles Translational Corp. Gyre is a biopharmaceutical company dedicated to advancing fibrosis-first therapies. Ping Zhang, Executive Chairman and Interim CEO of Gyre, stated that Dr. Weng’s strategic insight and regulatory experience will be invaluable as the company expands its commercial reach and advances its multi-national pipeline.
Gyre Pharmaceuticals’ pipeline includes Hydronidone, a structural analogue of pirfenidone, which demonstrated statistically significant fibrosis regression after 52 weeks of treatment in a pivotal Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC. Hydronidone received Breakthrough Therapy designation by the NMPA Center for Drug Evaluation in March 2021 and NDA filing is expected in the third quarter of 2025. Gyre Pharmaceuticals is also developing treatments for PD, DKD, RILI with or without immune-related pneumonitis, COPD, PAH and ALF/ACLF.
Gyre Therapeutics is headquartered in San Diego, CA, and is primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the United States.
David Zhang
Gyre Therapeutics
david.zhang@gyretx.com
Source: Gyre Therapeutics
